An act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act

Summary#

C-286, An Act to amend the Controlled Drugs and Substances Act and the Food and Drugs Act, would amend both Acts. It would change how psilocin and psilocybin are treated under certain drug regulations and automatically grant priority-review status to qualifying requests for certain new drug submissions. Its stated goal is to improve access to medical treatment involving these substances without bypassing existing drug-approval processes. The supplied material does not say whether the bill has passed or when the proposed changes would start.

• For purposes of the Narcotic Control Regulations, the bill would define “narcotic” to include psilocin, psilocybin and their salts, as well as specified controlled substances. It also addresses substances that midwives, nurse practitioners and podiatrists may prescribe, possess or use under the New Classes of Practitioners Regulations.
• For Part J of the Food and Drug Regulations, it would exclude psilocin, psilocybin and their salts from the definition of “restricted drug.” This is a specific change to that definition, not a general exemption from drug controls.
• A request made to the Department in accordance with its Priority Review of Drug Submissions Policy would automatically receive priority-review status if it concerns a new drug submission for psilocin, psilocybin, their salts, or a substance with a “substantially similar” chemical structure.
• Priority-review status would not itself approve a drug or guarantee that it can be sold or used.

What it means for you#

• Patients: The bill aims to improve access to medical treatment involving psilocin or psilocybin. It would not itself give patients a right to receive treatment or set out who qualifies.
• Midwives, nurse practitioners and podiatrists: The bill’s definition refers to controlled substances they may prescribe, possess or use under existing regulations. It does not set out new prescribing or treatment rules.
• Drug-submission applicants: Qualifying requests for priority review would be deemed granted when received, if submitted in accordance with the Department’s policy. The bill does not guarantee approval of the drug submission.
• Department of Health: The Department would have to treat qualifying requests as granted priority-review status. The bill does not set a review deadline.

Money#

No cost information is in the available material.

• The bill gives no spending estimate, staffing figure, fee change or funding source.
• It does not state what administrative costs, if any, the changes would create.

What is unclear#

• The Narcotic Control Regulations and the parent Acts are not supplied, so the bill’s effect alongside current rules could not be verified.
• The bill does not spell out the conditions or process for medical treatment; it refers to the Narcotic Control Regulations.
• “Substantially similar” is not defined in the bill.
• The Department’s priority-review policy is referenced but not supplied. The bill does not state how long review would take or how priority status would affect other submissions.
• The supplied text does not give a commencement date or show the bill’s status.

Case for#

• The bill appears intended to improve access to medical treatment involving psilocin and psilocybin by changing their treatment under specified regulations.
• Automatically granting priority-review status for qualifying submissions could give those submissions priority without bypassing the drug-approval process.
• The bill limits this automatic status to requests made in accordance with the Department’s policy and to named substances or substances with substantially similar chemical structures.

Case against#

• Priority-review status is not approval. The bill may speed up review status without ensuring a treatment becomes available.
• The bill does not define “substantially similar,” which could leave uncertainty about which substances qualify.
• The rules governing medical use are left to regulations not included in the supplied material, so the practical change for patients and practitioners is unclear.
• The bill does not explain how automatic priority status would affect review timelines or the Department’s workload.